Five PubMed papers to open first: cancer blood screening, Wiskott-Aldrich gene therapy, meningioma radiotherapy, fibrodysplasia ossificans progressiva, and pediatric ICU blood pressure
A ranked 10-minute triage of five papers entered in PubMed from September 22-29, 2026: a 142,250-participant randomized trial of a multicancer blood screening test, five-year outcomes of gene therapy for Wiskott-Aldrich syndrome, adjuvant radiotherapy after atypical meningioma resection, an activin A-blocking antibody in fibrodysplasia ossificans progressiva, and permissive blood-pressure targets in pediatric intensive care.
This issue covers the papers that entered PubMed between September 22 and September 29, 2026, using each record's PubMed entry date. Four report randomized comparisons and all five sit at the top of the impact tiers. Their citation counts cannot order them yet: across the three indexes that carry these records, the highest count for any of the five is three cited-by works, and two papers are too new to have an index entry at all. The order below rests on the strength of the evidence each paper carries — randomized design, sample size, and endpoint strength — and on how directly the result changes a treatment, screening, or monitoring decision.
At a glance
| Rank | Paper | Journal and tier | Design and sample | Primary result | Early cited-by signal |
|---|---|---|---|---|---|
| 1 | Screening with a multicancer early-detection blood test 1 | The New England Journal of Medicine; very high impact tier | Randomized, controlled trial in England; 142,250 people aged 50-77, three annual screening rounds | Stage III or IV cancer among 12 prespecified types: incidence rate ratio 1.03 (95% CI 0.92-1.14), P=.63; stage IV alone: 0.86 (0.74-1.00) | 3 2 |
| 2 | Gene therapy for Wiskott-Aldrich syndrome 3 | The New England Journal of Medicine; very high impact tier | Integrated phase 1-2 and phase 3 studies plus an expanded-access programme; 27 patients, single infusion | Overall survival 96% at 1 and 5 years; severe infections 2.00 to 0.15 events per person-year | 0 4 |
| 3 | Adjuvant radiotherapy for atypical meningioma 5 | The Lancet; very high impact tier | Phase 3, randomized, open-label trial at 58 hospitals in 11 countries; 157 patients | 5-year disease-free survival 79.9% vs 64.3%; hazard ratio 0.51 (95% CI 0.27-0.97), P=.0396 | 1 6 |
| 4 | Garetosmab in fibrodysplasia ossificans progressiva 7 | The Lancet; very high impact tier | Phase 3, randomized, double-blind, placebo-controlled trial at 18 sites in 16 countries; 63 adults | New heterotopic bone lesions 19 with placebo vs 1 with garetosmab 3 mg/kg (rate ratio 0.06, 95% CI 0.00-0.73), P=.027 | No OpenAlex record yet |
| 5 | Permissive blood-pressure targets in pediatric intensive care 8 | JAMA; very high impact tier | Multicentre, unblinded, pragmatic randomized trial in 23 pediatric intensive care units in 3 countries; 1,900 children | Composite of mortality and duration of invasive ventilation at 30 days: probabilistic index 0.52 (95% CI 0.49-0.54), P=.23 | No OpenAlex record yet |
1. Screening 142,000 people with a multicancer blood test: the stage at diagnosis held
Journal and impact tier: The New England Journal of Medicine, very high impact tier. PubMed entered the paper on September 23, 2026, under PMID 42776074. 1
Author and affiliation: First author Peter Sasieni is at Queen Mary University of London; senior author Charles Swanton is at University College London, and Peter Johnson is at NHS England. 1
Design, setting, and sample: NHS-Galleri is a randomized, controlled trial run across England, coordinated by the Cancer Research UK Cancer Prevention Trials Unit at Queen Mary University of London. People aged 50 to 77 gave a blood sample at up to three annual visits; after the first collection they were assigned 1:1 either to have that sample tested with a multicancer early-detection blood test or to have it stored. 142,250 participants were randomly assigned, 71,122 to the tested group and 71,128 to the stored group. The registry lists the trial as NCT05611632 (ISRCTN91431511), sponsored by GRAIL, with actual enrolment recorded as 142,318 and primary completion in June 2026. 9
Primary endpoint and quantitative result: The primary endpoint was incident stage III or IV cancer among 12 prespecified cancer types, measured as an incidence rate after three screening rounds and at least 12 months of follow-up after the last participant's third visit. The incidence rate ratio between the tested and stored groups was 1.03 (95% CI 0.92 to 1.14; P=.63). For stage IV cancer alone, a key secondary endpoint, the incidence rate ratio was 0.86 (95% CI 0.74 to 1.00). Fewer than 1% of participants had trial-related adverse events, none of them serious. 1
Why it matters: A blood test that looks for many cancers at once is the most heavily promoted idea in cancer screening, and until now the evidence behind it has been detection yield: how many cancers the test finds, and at what stage. This trial asks the question that decides screening programmes instead — whether offering the test moves the stage at which cancers are diagnosed in a whole population. On the prespecified endpoint it landed at parity, and the stage IV signal points in the favourable direction with an interval that reaches 1.00. The journal's accompanying editorial reads the result as one step in a search that remains open. 10
Limitation and evidence boundary: The 12 prespecified cancer types and the stage III or IV endpoint define what was tested; other cancers and other endpoints were not. The stage IV result is a secondary endpoint, and its confidence interval touches 1.00, so the paper's own reading is that further follow-up is needed to see how the two endpoints evolve. The tested population was 50 to 77 years old in England, and the paper reports that participants and trial personnel were initially unaware of group assignment. The test's manufacturer funded the trial, which is worth holding alongside the result. 1
Funding or disclosure: Funded by GRAIL, the manufacturer of the Galleri test; registered as NCT05611632 and ISRCTN91431511. 9
2. One gene-therapy infusion for Wiskott-Aldrich syndrome: 96% survival at five years
Journal and impact tier: The New England Journal of Medicine, very high impact tier; volume 395, issue 12, pages 1193-1205. PubMed entered the paper on September 23, 2026, under PMID 42777242. 3
Author and affiliation: First author Francesca Ferrua is at the San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, in Milan; senior author Alessandro Aiuti is at the same institute, where the studies were run. The report is issued for the WAS Gene Therapy Group. 3
Design, setting, and sample: This is an integrated analysis of two prospective, open-label studies plus an expanded-access programme. The phase 1-2 study enrolled 8 participants and the phase 3 study 10, with 9 more treated under expanded access, giving 27 patients. Participants received a single intravenous infusion of their own hematopoietic stem and progenitor cells, transduced outside the body with a lentiviral vector carrying functional WAS complementary DNA, after rituximab and reduced-intensity conditioning. Median age at gene therapy was 2.6 years (range 1.0 to 35.1), and median follow-up among surviving participants was 5.7 years (range 2.3 to 13.3). The phase 1-2 study is registered as NCT01515462 and the phase 3 study as NCT03837483, both sponsored by Fondazione Telethon. 1112
Primary endpoint and quantitative result: The primary efficacy endpoints were overall survival, severe infections from 6 to 18 months after gene therapy, and moderate or severe bleeding events in the first 12 months. Infection and bleeding are reported as rates per person-year, compared with the rate in the year before gene therapy. Overall survival was 96% at both 1 year and 5 years, with one death among the 27 patients. Severe infections fell from 2.00 events per person-year (95% CI 1.50 to 2.61) before gene therapy to 0.15 (95% CI 0.04 to 0.39) beyond 6 months up to 18 months after it, and moderate or severe bleeding fell from 2.00 (1.50 to 2.61) to 0.80 (0.49 to 1.22) in the first year. The most common grade 3 or higher adverse event was central venous catheter-related infection, and the investigators observed no evidence of insertional oncogenesis. 3
Why it matters: Wiskott-Aldrich syndrome is an X-linked disorder that combines immune deficiency with a platelet defect, and its established cure is allogeneic hematopoietic stem cell transplantation, which depends on finding a suitable donor and carries graft-versus-host disease and long-term immunosuppression with it. A single infusion of gene-corrected cells took severe infections from two per year to one every several years, and left 96% of patients alive at five years, in a group whose median age was under three. For a clinician weighing referral for a young patient with the disorder, this is the durability evidence that decides whether the one-time option is real. 3
Limitation and evidence boundary: The population is 27 patients across three programmes, and the infection and bleeding comparisons are each patient against their own previous year, which is a before-and-after comparison rather than a randomized one; the phase 1-2 and phase 3 studies were open-label. Five to six years of median follow-up is long for a correction of this kind and short against the decades over which insertional oncogenesis can appear, which is why the absence of such an event so far is a finding to keep checking rather than a closed question. The median age of 2.6 years means the result speaks most directly to treatment in early childhood, with the enrolled range extending to 35.1 years. 3
Funding or disclosure: Funded by Fondazione Telethon and others; registered as NCT01515462 (TIGET-WAS) and NCT03837483 (OTL-103-4). 3
3. Radiotherapy after complete resection of an atypical meningioma: recurrence falls from 30% to 14%
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the paper on September 25, 2026, under PMID 42790456. 5
Author and affiliation: First and corresponding author Michael D. Jenkinson is at the Institute of Systems, Molecular and Integrative Biology, University of Liverpool, and The Walton Centre NHS Foundation Trust, in the United Kingdom; trial statistician Anna Rosala-Hallas is at the Liverpool Clinical Trials Centre, University of Liverpool. The individual author list closes with Damien C. Weber at the Paul Scherrer Institute and Bern University Hospital, and the report is issued for the ROAM/1308 Study Collaborators. 5
Design, setting, and sample: ROAM/EORTC-1308 is an international, multicentre, open-label, phase 3 randomized trial at 58 hospitals and academic centres in 11 countries. Patients aged 16 or older who had undergone a surgeon-assessed complete resection of a newly diagnosed WHO grade 2 atypical meningioma were assigned 1:1 to adjuvant radiotherapy at 60 Gy in 30 fractions over 6 weeks or to observation, with follow-up for a minimum of four years. 990 patients were assessed for eligibility and 157 were randomly assigned — 78 to radiotherapy and 79 to observation — with a median age of 57.4 years. The trial is registered with ISRCTN, ISRCTN71502099, and has completed. 5
Primary endpoint and quantitative result: The primary outcome was disease-free survival, from surgery to MRI-confirmed recurrence or death from any cause. At a median follow-up of 64 months (IQR 50 to 75), recurrence occurred in 11 of 78 participants (14%) given radiotherapy and 24 of 79 (30%) under observation. Five-year disease-free survival was 79.9% (95% CI 67.6 to 87.9) with radiotherapy against 64.3% (51.9 to 74.2) with observation — an absolute difference of 15.6 percentage points (95% CI 0.6 to 30.5), for a hazard ratio of 0.51 (95% CI 0.27 to 0.97; P=.0396). Grade 2 or 3 radiation-related serious adverse events occurred in 5 of the 66 participants (8%) who received radiotherapy, and there were no treatment-related deaths. 5
Why it matters: Atypical meningioma recurs in a substantial share of patients even after the surgeon reports a complete resection, and whether to irradiate the tumour bed afterwards has been an open question with practice varying between centres. This trial's own conclusion is that adjuvant radiotherapy should be considered when preventing recurrence is valued above the delayed adverse effects of radiation, with the decision made in discussion with the individual patient — a formulation that hands the trade-off to the clinic rather than settling it. The journal ran an accompanying comment on the same question. 13
Limitation and evidence boundary: The trial randomized 157 of the 990 patients assessed, so its answer comes from a selected group whose surgeons judged resection complete, and the effect estimate carries a wide interval — the absolute benefit could be as small as 0.6 percentage points or as large as 30.5. Participants and clinicians knew the assigned arm, and only the analysis was fixed in advance. The endpoint is recurrence and death, so quality of life and cognitive effects after 60 Gy to the tumour bed lie outside what this report measures. 5
Funding or disclosure: Funded by the National Institute for Health and Care Research Health Technology Assessment programme, the European Organisation for Research and Treatment of Cancer Brain Tumour Group and Radiation Oncology Group, and the National Health and Medical Research Council of Australia; registered as ISRCTN71502099. 5
4. Blocking activin A in fibrodysplasia ossificans progressiva: 19 new bone lesions become one
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the paper on September 28, 2026, under PMID 42805227. 7
Author and affiliation: First author Riccardo Papa is in the Division of Rheumatology and Autoinflammatory Diseases at IRCCS Istituto Giannina Gaslini in Genova, Italy; corresponding author Susan Rhee is at Regeneron Pharmaceuticals in Tarrytown, New York. The author list closes with Richard Keen of the Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital NHS Trust, London, and the report is issued for the OPTIMA Study Group. 7
Design, setting, and sample: OPTIMA is a randomized, double-blind, placebo-controlled phase 3 trial at 18 study sites in 16 countries. Adults aged 18 or older with fibrodysplasia ossificans progressiva were assigned 1:1:1 to monthly intravenous placebo, garetosmab 3 mg/kg, or garetosmab 10 mg/kg, stratified by a baseline joint involvement score and by whether they had taken part in the earlier phase 2 trial. 63 participants were enrolled between November 2022 and July 2024 — 21 assigned to placebo, 19 to garetosmab 3 mg/kg, and 23 to 10 mg/kg — and 62 completed 56 weeks of treatment. The registry records 63 actual participants, quadruple masking, and Regeneron Pharmaceuticals as sponsor. 14
Primary endpoint and quantitative result: The co-primary endpoints were the total number of new heterotopic bone lesions at week 56 and treatment-emergent adverse events of special interest through week 56. The 21 participants on placebo developed 19 new lesions, against 1 among the 19 given garetosmab 3 mg/kg (rate ratio 0.06, 95% CI 0.00 to 0.73; P=.027) and 2 among the 23 given 10 mg/kg (rate ratio 0.10, 95% CI 0.01 to 0.76; P=.026). Adverse events of special interest occurred in 1 of 21 participants on placebo (5%), none of 19 on 3 mg/kg, and 4 of 23 (17%) on 10 mg/kg, all judged treatment-related, with no deaths. 7
Why it matters: The mechanism here is unusually direct. Fibrodysplasia ossificans progressiva comes from gain-of-function variants in the activin receptor type 1A, which let activin A switch the receptor on where it normally switches it off, and the result is bone that forms inside muscles, tendons, and ligaments over a lifetime and removes movement as it accumulates. Garetosmab blocks activin A, so a phase 3 trial of it is a test of the causal pathway as much as of a drug. New lesions fell from 19 to one or two over 56 weeks in the two dose groups, which is the first phase 3 evidence in adults that the process can be interrupted; the journal's accompanying comment frames the antibody as a new and effective treatment for the condition. 15
Limitation and evidence boundary: With 63 participants and arms of 19 to 23, the confidence intervals run against the edge of what a rate ratio can express — the lower bound for the 3 mg/kg group is 0.00. What is counted is new lesions over 56 weeks, which is a measure of the process rather than of what the reader cares about in the clinic, namely movement, disability, and how much bone has already formed. The adverse event signal sits with the higher dose: 17% of the 10 mg/kg group had an event of special interest against none at 3 mg/kg, so the dose question stays open as the trial continues. 7
Funding or disclosure: Funded by Regeneron Pharmaceuticals, the developer of garetosmab; registered as NCT05394116. 14
5. A permissive blood-pressure target in pediatric intensive care: 37.5% less vasoactive drug
Journal and impact tier: JAMA, very high impact tier. PubMed entered the paper on September 29, 2026, under PMID 42806496. 8
Author and affiliation: First author David P. Inwald is at the Paediatric Intensive Care Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, in England; Emma Laing and Paul R. Mouncey are at the Intensive Care National Audit and Research Centre in London. The report is issued by the PRESSURE trial investigators on behalf of the United Kingdom Paediatric Critical Care Society Study Group. 8
Design, setting, and sample: PRESSURE is a multicentre, unblinded, pragmatic randomized trial in 23 pediatric intensive care units across three countries. Children who were receiving invasive ventilation and vasoactive drugs for hypotension were enrolled between November 2021 and May 2026, with follow-up to the 30-day outcome completed in June 2026. 1,900 patients were randomly assigned — 957 to a permissive mean arterial pressure target above the fifth percentile for age and 943 to usual care with the target set by the attending physician — leaving 910 and 904 in the primary analysis, at a median age of 4 years. The trial is registered as ISRCTN20609635 and SNCTP000006590. 8
Primary endpoint and quantitative result: The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days. The permissive target group and the usual care group came out together on that composite (probabilistic index 0.52, 95% CI 0.49 to 0.54; P=.23). Median mean arterial pressure while on vasoactive drugs was 58 mm Hg (IQR 51 to 63) under the permissive target and 61 (54 to 67) under usual care, and the permissive target produced a 37.5% reduction in the median norepinephrine-equivalent dose. Six of the seven secondary outcomes were similar between groups; the exception was a shorter intensive care stay among survivors, 159 hours (IQR 79 to 286) against 166 (92 to 319), probabilistic index 0.53 (95% CI 0.50 to 0.56). Receipt of kidney replacement therapy and adverse events were similar. 8
Why it matters: In a hypotensive ventilated child the bedside question is how much vasoactive drug to give, and the threshold that triggers it has been a matter of attending preference rather than evidence. This trial assigns the threshold and reports the trade in numbers a reader can use: about 3 mm Hg lower mean arterial pressure buys a 37.5% lower median drug dose, and the composite of mortality and ventilation duration lands at the same place either way. For a unit deciding what its default target should be, that is the comparison to reason from. 8
Limitation and evidence boundary: The intervention is a target rather than a drug, so participants and clinicians knew the assigned arm, and only the outcome adjudication was kept at arm's length. The primary result comes from a composite of mortality and ventilation duration, which can move in opposite directions without the composite changing, and the probabilistic index interval includes 0.50. One of seven secondary outcomes differed between groups. The one positive signal, a shorter intensive care stay, is a secondary endpoint, so it belongs in the reader's notes rather than in a protocol. 8
Funding or disclosure: The paper's registration line gives ISRCTN20609635 and the Swiss National Clinical Trial Portal number SNCTP000006590; the PubMed record lists no funding grant for the trial. 8
What to open first
- Screening with a blood test for many cancers: Open NHS-Galleri if your question is whether adding the test to usual care moves the stage at which 12 cancers are diagnosed, and how a stage IV signal should be weighed when the prespecified endpoint landed at parity. 1
- Gene therapy for an inherited immune and platelet disorder: Open the etu-cel report if your question is how much of the burden of Wiskott-Aldrich syndrome a single lentiviral infusion removes across five years, and what the record on insertional risk looks like so far. 3
- Atypical meningioma after a complete resection: Open ROAM if your question is how much adjuvant radiotherapy lowers recurrence, and what a 157-patient trial with a wide confidence interval can settle about irradiating the tumour bed. 5
- Fibrodysplasia ossificans progressiva: Open OPTIMA if your question is whether blocking activin A stops new heterotopic bone from forming in adults with the condition, and how lesion counts relate to the disability they cause. 7
- Blood-pressure targets in pediatric intensive care: Open PRESSURE if your question is how much vasoactive drug can be withheld under a permissive mean arterial pressure target, and what that does to mortality and time on the ventilator. 8
The week's five results fall into two groups. Two of them tested whether a change in what the clinician does — testing every participant's blood sample, or accepting a lower pressure target before starting vasoactive drugs — alters the primary endpoint, and both found the endpoint where it stood before, with secondary signals in the direction the investigators hoped for. The other three report positive effects in a rare inherited immune disorder, a rare brain tumour, and an ultrarare disease of heterotopic bone formation, each in a population small enough that the confidence interval is the part of the result to carry away. Every number above holds only for the patients who were enrolled in the study that produced it.
References
- 1Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
pubmed.ncbi.nlm.nih.gov
- 2OpenAlex record for the NHS-Galleri report
openalex.org
- 3Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome
pubmed.ncbi.nlm.nih.gov
- 4OpenAlex record for the etu-cel report
openalex.org
- 5
- 6OpenAlex record for the ROAM/EORTC-1308 report
openalex.org
- 7
- 8
- 9
- 10A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer
pubmed.ncbi.nlm.nih.gov
- 11Gene Therapy for Wiskott-Aldrich Syndrome
clinicaltrials.gov
- 12
- 13Adjuvant radiotherapy for atypical meningioma
pubmed.ncbi.nlm.nih.gov
- 14
- 15A novel and effective treatment for fibrodysplasia ossificans progressiva
pubmed.ncbi.nlm.nih.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.